About Us

News Releases

12.11.14
Parent Project Muscular Dystrophy To Collaborate With Catabasis Pharmaceuticals, Inc. On CAT-1004 Development

11.24.14
Catabasis Pharmaceuticals Receives FDA Orphan Drug Designation for CAT-1004 for the Treatment of Duchenne Muscular Dystrophy

11.18.14
Catabasis Names Angelika Fretzen, Ph.D., Vice President of Development

09.30.14
Catabasis Pharmaceuticals Management to Present at October Investor Conferences

09.29.14
Catabasis Pharmaceuticals to Present at International Congress of the World Muscle Society

08.06.14
Catabasis Pharmaceuticals to Present at Wedbush 2014 Life Sciences Management Access Conference

06.24.14
Catabasis Pharmaceuticals to Present at Parent Project Muscular Dystrophy (PPMD) Annual Connect Conference and New Directions in Biology and Disease of Skeletal Muscle Conference

06.11.14
Catabasis Pharmaceuticals Announces Issuance of Three New US Patents for CAT-1000 Series

05.02.14
Catabasis Demonstrates CAT-2003 Lowers Fed and Fasting Triglycerides in Studies Presented at Lipid Conferences

05.01.14
Catabasis Describes Modulation of SREBP as Mechanism for CAT-2003

04.25.14
Catabasis to Present CAT-2003 Data at Upcoming Lipid Conferences

03.31.14
Catabasis to Present CAT-2003 Data at the American College of Cardiology’s 63rd Annual Scientific Session

03.14.14
Catabasis to Present Data on CAT-1004 at the Muscular Dystrophy Association’s 2014 Clinical Conference

02.26.14
Catabasis Names Andrew Nichols, Ph.D., Vice President of Research

02.04.14
Catabasis Announces Appointment of Kenneth M. Bate as Independent Director

01.08.14
Catabasis to Present at 32nd Annual J.P. Morgan Healthcare Conference

12.05.13
Catabasis Initiates Phase 2 Trial of CAT-2003 in Patients with Severe Hypertriglyceridemia

11.15.13
Catabasis Closes $32.4 Million Series B Financing

11.13.13
Catabasis Names Ian Sanderson Chief Financial Officer

08.28.13
Catabasis to Present Phase 1 Data from Oral SMART Linker Conjugate CAT-2003 at Upcoming Conference

08.21.13
Catabasis Initiates Phase 2 Trial of CAT-2003 in Patients with Hypertriglyceridemia and Hypercholesterolemia

07.30.13
Catabasis’ CAT-2003 Demonstrates Significant Reduction of Fasting and Post-Prandial Triglycerides in Successful Phase 1 Trial

04.30.13
Catabasis Pharmaceuticals Announces Issuance of Patents for CAT-1000 and CAT-2000 Series

03.26.13
Catabasis Initiates Phase 1 Trial of CAT-2003 for Treatment of Severe Hypertriglyceridemia

02.11.13
Catabasis Announces Positive Phase 1 Data for CAT-1004 Validating the SMART Linker Technology Platform

12.06.12
Catabasis Pharmaceuticals to Present at Upcoming December Conference

11.08.12
Catabasis Pharmaceuticals to Present at Upcoming November Conferences

06.06.12
Catabasis Pharmaceuticals to Present at Parent Project Muscular Dystrophy (PPMD) Annual Connect Conference

05.31.12
Catabasis Pharmaceuticals Appoints Henry Rath to Vice President, Business Development

04.04.12
MDA Awards a Second Grant to Catabasis to Study Muscular Dystrophy

03.28.12
Catabasis Pharmaceuticals to Present at Upcoming Investor and Industry Conferences

02.29.12
Catabasis Pharmaceuticals to Present at Upcoming Investor and Industry Conferences

12.13.11
Catabasis Pharmaceuticals Announces $8 Million Series A Extension Financing

11.22.11
Catabasis Pharmaceuticals to Present at Upcoming Industry and Investment Conferences

11.02.11
Catabasis Pharmaceuticals Promotes Michael Curtis, Ph.D., to Senior Vice President, Product Development and Regulatory Affairs

10.19.11
Catabasis Pharmaceuticals to Present at Upcoming Conferences

10.05.11
Catabasis Pharmaceuticals Initiates Phase 1 Clinical Trial of Lead Compound CAT-1004

09.08.11
Catabasis Pharmaceuticals Appoints Joanne M. Donovan, M.D., Ph.D., to Chief Medical Officer

06.14.11
Catabasis Pharmaceuticals Expands Leadership Team and Appoints Leading Experts to Clinical Advisory Board

12.08.10
Catabasis Pharmaceuticals Secures $14.5 Million Second Tranche in Series A Financing

10.14.10
Catabasis Pharmaceuticals Appoints Michael Curtis, Ph.D., as Vice President, Product Development

09.15.10
Catabasis Pharmaceuticals Named One of the "Fierce 15" Leading Biotech Companies of 2010

04.21.10
Catabasis Pharmaceuticals Secures $39.6 Million Series A Funding

 

 

Return to Health